

# Effect of repeated three-monthly albendazole treatments on malaria and allergic disease

<b>Submission date</b> 08/12/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 27/02/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 02/12/2019	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Maria Yazdanbakhsh

**Contact details**  
Department of Parasitology  
Leiden University Medical Centre  
Albinusdreef 2  
Leiden  
Netherlands  
2333 ZA  
-  
M.Yazdanbakhsh@lumc.nl

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
05-PP-35

# Study information

## Scientific Title

Parasitic infections and Inflammatory Diseases: The web of immune responses, host genetics and environmental exposure

## Study objectives

Intestinal helminth infections suppress atopy and incidence of malaria and this suppression is reversible by antihelminthic treatment

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

University of Indonesia, approved on 11/09/2006 (ref: 194/ PT02.FK/Etik/2006)

## Study design

Randomised double-blind placebo-controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Other

## Study type(s)

Prevention

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Helminth and malaria parasitic diseases

## Interventions

400 mg albendazole (oral) or matching placebo every three months for 2 years.

## Intervention Type

Other

## Phase

Not Applicable

## Primary outcome measure

1. Prevalence of malaria parasite, assessed throughout the study for 3 years
2. Infection with intestinal helminth before treatment and within 1, 2 and 3 years after start of

treatment

3. Skin reactivity to allergens assessed before treatment and within 1, 2 and 3 years after start of treatment

### **Secondary outcome measures**

Immune response to malaria and helminth antigens, assessed before albendazole treatment and within 1, 2 and 3 years after the start of treatment (with the last treatment given at least 2 months before immunological determination).

### **Overall study start date**

01/11/2008

### **Completion date**

01/11/2011

## **Eligibility**

### **Key inclusion criteria**

1. Both males and females
2. Age  $\geq 2$  years. No upper age limit.
3. Those who have given informed consent

### **Participant type(s)**

Patient

### **Age group**

Other

### **Sex**

Both

### **Target number of participants**

4,000

### **Total final enrolment**

4004

### **Key exclusion criteria**

1. History of chronic liver, heart or central nervous system (CNS) disease
2. Allergy to albendazole

### **Date of first enrolment**

01/11/2008

### **Date of final enrolment**

01/11/2011

## **Locations**

### **Countries of recruitment**

Indonesia

Netherlands

**Study participating centre**  
**Department of Parasitology**  
Leiden  
Netherlands  
2333 ZA

## **Sponsor information**

### **Organisation**

Royal Netherlands Academy of Arts and Sciences (Netherlands)

### **Sponsor details**

Kloveniersburgwal 29  
Amsterdam  
Netherlands  
1011 JV

-

knaw@bureau.knaw.nl

### **Sponsor type**

University/education

### **Website**

<http://www.knaw.nl>

### **ROR**

<https://ror.org/043c0p156>

## **Funder(s)**

### **Funder type**

University/education

### **Funder Name**

Royal Netherlands Academy of Arts and Sciences (Netherlands) (ref: 05-PP-35)

### **Alternative Name(s)**

Royal Netherlands Academy of Arts and Sciences, KNAW

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

Netherlands

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2013		Yes	No
<a href="#">Results article</a>	results	09/08/2018		Yes	No
<a href="#">Results article</a>	gut microbiome results	06/11/2019	02/12/2019	Yes	No